Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: Correlation of protein expression and GC/TOF-MS-based metabolomics

Ann Christin Buckendahl, Jan Budczies, Oliver Fiehn, Silvia Darb-Esfahani, Tobias Kind, Aurelia Noske, Wilko Weichert, Jalid Sehouli, Elena Braicu, Manfred Dietel, Carsten Denkert

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

AMP-activated protein kinase (AMPK) plays a central role in regulating energy metabolism in cells. AMPK activation results in down-regulation of anabolic pathways (e.g., fatty acid biosynthesis) and switches on catabolic processes such as glucose uptake, glycolysis or fatty acid oxidation. Recent studies in cell culture models have shown that the growth of tumor cell lines was inhibited by AMPK activation, but the expression of AMPK in human ovarian tumors has not been reported so far. In this study we investigated AMPK expression in a cohort of 70 ovarian carcinomas, 14 borderline tumors and 5 normal ovaries and linked the protein expression data to Gas chromatography/time of flight mass spectrometry (GC/TOF-MS) based metabolomics. We observed a significantly higher expression in ovarian carcinomas compared to borderline tumors and normal ovaries (p=0.038). Decreased AMPK expression correlated significantly with higher tumor grade (p=0.009) and was of adverse prognosis in patients with advanced tumor stages (p=0.016) as well as in patients with serous ovarian carcinomas (p=0.037). GC/TOF-MS based metabolomics revealed a significantly higher concentration of glucose in AMPK-negative carcinomas (p=0.022) as well as overexpression of other metabolites from carbohydrate metabolism. Our results indicate a role for AMPK in progression of ovarian tumors and point towards a prognostic impact of AMPK expression for patient overall survival. Furthermore, our data suggest a deregulation of the AMPK-dependent energy metabolism in human ovarian carcinomas. In future clinical studies, activation of AMPK in ovarian carcinoma patients with advanced tumor stages might be an interesting therapeutic approach.

Original languageEnglish (US)
Pages (from-to)1005-1012
Number of pages8
JournalOncology Reports
Volume25
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

AMP-Activated Protein Kinases
Metabolomics
Gas Chromatography
Mass Spectrometry
Carcinoma
Proteins
Neoplasms
Energy Metabolism
Ovary
Fatty Acids
Glucose
Carbohydrate Metabolism
Glycolysis
Tumor Cell Line
Down-Regulation
Cell Culture Techniques

Keywords

  • AMP-activated protein kinase
  • Energy metabolism
  • Immunohistochemistry
  • Metabolomics
  • Ovarian carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma : Correlation of protein expression and GC/TOF-MS-based metabolomics. / Buckendahl, Ann Christin; Budczies, Jan; Fiehn, Oliver; Darb-Esfahani, Silvia; Kind, Tobias; Noske, Aurelia; Weichert, Wilko; Sehouli, Jalid; Braicu, Elena; Dietel, Manfred; Denkert, Carsten.

In: Oncology Reports, Vol. 25, No. 4, 04.2011, p. 1005-1012.

Research output: Contribution to journalArticle

Buckendahl, AC, Budczies, J, Fiehn, O, Darb-Esfahani, S, Kind, T, Noske, A, Weichert, W, Sehouli, J, Braicu, E, Dietel, M & Denkert, C 2011, 'Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: Correlation of protein expression and GC/TOF-MS-based metabolomics', Oncology Reports, vol. 25, no. 4, pp. 1005-1012. https://doi.org/10.3892/or.2011.1162
Buckendahl, Ann Christin ; Budczies, Jan ; Fiehn, Oliver ; Darb-Esfahani, Silvia ; Kind, Tobias ; Noske, Aurelia ; Weichert, Wilko ; Sehouli, Jalid ; Braicu, Elena ; Dietel, Manfred ; Denkert, Carsten. / Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma : Correlation of protein expression and GC/TOF-MS-based metabolomics. In: Oncology Reports. 2011 ; Vol. 25, No. 4. pp. 1005-1012.
@article{e05d9faf9c494eacb5835a8de7c2eae8,
title = "Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: Correlation of protein expression and GC/TOF-MS-based metabolomics",
abstract = "AMP-activated protein kinase (AMPK) plays a central role in regulating energy metabolism in cells. AMPK activation results in down-regulation of anabolic pathways (e.g., fatty acid biosynthesis) and switches on catabolic processes such as glucose uptake, glycolysis or fatty acid oxidation. Recent studies in cell culture models have shown that the growth of tumor cell lines was inhibited by AMPK activation, but the expression of AMPK in human ovarian tumors has not been reported so far. In this study we investigated AMPK expression in a cohort of 70 ovarian carcinomas, 14 borderline tumors and 5 normal ovaries and linked the protein expression data to Gas chromatography/time of flight mass spectrometry (GC/TOF-MS) based metabolomics. We observed a significantly higher expression in ovarian carcinomas compared to borderline tumors and normal ovaries (p=0.038). Decreased AMPK expression correlated significantly with higher tumor grade (p=0.009) and was of adverse prognosis in patients with advanced tumor stages (p=0.016) as well as in patients with serous ovarian carcinomas (p=0.037). GC/TOF-MS based metabolomics revealed a significantly higher concentration of glucose in AMPK-negative carcinomas (p=0.022) as well as overexpression of other metabolites from carbohydrate metabolism. Our results indicate a role for AMPK in progression of ovarian tumors and point towards a prognostic impact of AMPK expression for patient overall survival. Furthermore, our data suggest a deregulation of the AMPK-dependent energy metabolism in human ovarian carcinomas. In future clinical studies, activation of AMPK in ovarian carcinoma patients with advanced tumor stages might be an interesting therapeutic approach.",
keywords = "AMP-activated protein kinase, Energy metabolism, Immunohistochemistry, Metabolomics, Ovarian carcinoma",
author = "Buckendahl, {Ann Christin} and Jan Budczies and Oliver Fiehn and Silvia Darb-Esfahani and Tobias Kind and Aurelia Noske and Wilko Weichert and Jalid Sehouli and Elena Braicu and Manfred Dietel and Carsten Denkert",
year = "2011",
month = "4",
doi = "10.3892/or.2011.1162",
language = "English (US)",
volume = "25",
pages = "1005--1012",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma

T2 - Correlation of protein expression and GC/TOF-MS-based metabolomics

AU - Buckendahl, Ann Christin

AU - Budczies, Jan

AU - Fiehn, Oliver

AU - Darb-Esfahani, Silvia

AU - Kind, Tobias

AU - Noske, Aurelia

AU - Weichert, Wilko

AU - Sehouli, Jalid

AU - Braicu, Elena

AU - Dietel, Manfred

AU - Denkert, Carsten

PY - 2011/4

Y1 - 2011/4

N2 - AMP-activated protein kinase (AMPK) plays a central role in regulating energy metabolism in cells. AMPK activation results in down-regulation of anabolic pathways (e.g., fatty acid biosynthesis) and switches on catabolic processes such as glucose uptake, glycolysis or fatty acid oxidation. Recent studies in cell culture models have shown that the growth of tumor cell lines was inhibited by AMPK activation, but the expression of AMPK in human ovarian tumors has not been reported so far. In this study we investigated AMPK expression in a cohort of 70 ovarian carcinomas, 14 borderline tumors and 5 normal ovaries and linked the protein expression data to Gas chromatography/time of flight mass spectrometry (GC/TOF-MS) based metabolomics. We observed a significantly higher expression in ovarian carcinomas compared to borderline tumors and normal ovaries (p=0.038). Decreased AMPK expression correlated significantly with higher tumor grade (p=0.009) and was of adverse prognosis in patients with advanced tumor stages (p=0.016) as well as in patients with serous ovarian carcinomas (p=0.037). GC/TOF-MS based metabolomics revealed a significantly higher concentration of glucose in AMPK-negative carcinomas (p=0.022) as well as overexpression of other metabolites from carbohydrate metabolism. Our results indicate a role for AMPK in progression of ovarian tumors and point towards a prognostic impact of AMPK expression for patient overall survival. Furthermore, our data suggest a deregulation of the AMPK-dependent energy metabolism in human ovarian carcinomas. In future clinical studies, activation of AMPK in ovarian carcinoma patients with advanced tumor stages might be an interesting therapeutic approach.

AB - AMP-activated protein kinase (AMPK) plays a central role in regulating energy metabolism in cells. AMPK activation results in down-regulation of anabolic pathways (e.g., fatty acid biosynthesis) and switches on catabolic processes such as glucose uptake, glycolysis or fatty acid oxidation. Recent studies in cell culture models have shown that the growth of tumor cell lines was inhibited by AMPK activation, but the expression of AMPK in human ovarian tumors has not been reported so far. In this study we investigated AMPK expression in a cohort of 70 ovarian carcinomas, 14 borderline tumors and 5 normal ovaries and linked the protein expression data to Gas chromatography/time of flight mass spectrometry (GC/TOF-MS) based metabolomics. We observed a significantly higher expression in ovarian carcinomas compared to borderline tumors and normal ovaries (p=0.038). Decreased AMPK expression correlated significantly with higher tumor grade (p=0.009) and was of adverse prognosis in patients with advanced tumor stages (p=0.016) as well as in patients with serous ovarian carcinomas (p=0.037). GC/TOF-MS based metabolomics revealed a significantly higher concentration of glucose in AMPK-negative carcinomas (p=0.022) as well as overexpression of other metabolites from carbohydrate metabolism. Our results indicate a role for AMPK in progression of ovarian tumors and point towards a prognostic impact of AMPK expression for patient overall survival. Furthermore, our data suggest a deregulation of the AMPK-dependent energy metabolism in human ovarian carcinomas. In future clinical studies, activation of AMPK in ovarian carcinoma patients with advanced tumor stages might be an interesting therapeutic approach.

KW - AMP-activated protein kinase

KW - Energy metabolism

KW - Immunohistochemistry

KW - Metabolomics

KW - Ovarian carcinoma

UR - http://www.scopus.com/inward/record.url?scp=79952215103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952215103&partnerID=8YFLogxK

U2 - 10.3892/or.2011.1162

DO - 10.3892/or.2011.1162

M3 - Article

C2 - 21271224

AN - SCOPUS:79952215103

VL - 25

SP - 1005

EP - 1012

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -